Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01439880




Registration number
NCT01439880
Ethics application status
Date submitted
22/09/2011
Date registered
23/09/2011
Date last updated
21/09/2022

Titles & IDs
Public title
Open Label Study of Long Term Evaluation Against LDL-C Trial
Scientific title
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)
Secondary ID [1] 0 0
2011-001915-29
Secondary ID [2] 0 0
20110110
Universal Trial Number (UTN)
Trial acronym
OSLER
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypercholesterolemia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Evolocumab
Other interventions - Standard of care

Active comparator: Standard of Care - Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product \[all-IP\] period.

Experimental: Evolocumab + SOC - Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.


Treatment: Other: Evolocumab
Administered by subcutaneous injection

Other interventions: Standard of care
Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Adverse Events
Timepoint [1] 0 0
52 weeks in the SOC-controlled period and up to 4 years in the All-IP period; actual median duration of treatment in the All-IP period was 46.9 months.
Secondary outcome [1] 0 0
Low-density Lipoprotein Cholesterol (LDL-C) Level at Week 24 and Week 52
Timepoint [1] 0 0
Baseline of parent study and extension study weeks 24 and 52
Secondary outcome [2] 0 0
Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Level at Week 24 and Week 52
Timepoint [2] 0 0
Baseline of parent study and extension study weeks 24 and 52
Secondary outcome [3] 0 0
Apolipoprotein B Level at Week 24 and Week 52
Timepoint [3] 0 0
Baseline of parent study and extension study weeks 24 and 52
Secondary outcome [4] 0 0
Total Cholesterol/HDL-C Ratio at Week 24 and Week 52
Timepoint [4] 0 0
Baseline of parent study and extension study weeks 24 and 52
Secondary outcome [5] 0 0
Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24 and Week 52
Timepoint [5] 0 0
Baseline of parent study and extension study weeks 24 and 52

Eligibility
Key inclusion criteria
* Complete a qualifying evolocumab (AMG 145) parent study protocol, including: 20101154 (NCT01375777), 20101155 (NCT01380730), 20090158 (NCT01375751), 20090159 (NCT01375764), and 20110231 (NCT01652703)
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Experienced a treatment-related serious adverse event that led to investigational product (IP) discontinuation in the parent study
* Have an unstable medical condition, in the judgment of the investigator
* Known sensitivity to any of the products to be administered during dosing
* Currently enrolled in another investigational device or drug study (excluding evolocumab (AMG 145) parent study), or less than 30 days since ending another investigational device or drug study(s),or receiving other investigational agent(s)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/10/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/06/2018
Sample size
Target
Accrual to date
Final
1324
Recruitment in Australia
Recruitment state(s)
NSW,WA
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Maroubra
Recruitment hospital [3] 0 0
Research Site - Sydney
Recruitment hospital [4] 0 0
Research Site - Perth
Recruitment postcode(s) [1] 0 0
2015 - Camperdown
Recruitment postcode(s) [2] 0 0
2035 - Maroubra
Recruitment postcode(s) [3] 0 0
2022 - Sydney
Recruitment postcode(s) [4] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Maine
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Minnesota
Country [17] 0 0
United States of America
State/province [17] 0 0
Mississippi
Country [18] 0 0
United States of America
State/province [18] 0 0
Montana
Country [19] 0 0
United States of America
State/province [19] 0 0
Nevada
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
North Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
South Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
South Dakota
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Washington
Country [32] 0 0
Belgium
State/province [32] 0 0
Anthée
Country [33] 0 0
Belgium
State/province [33] 0 0
Bruxelles
Country [34] 0 0
Belgium
State/province [34] 0 0
Gozee
Country [35] 0 0
Belgium
State/province [35] 0 0
Gribomont
Country [36] 0 0
Belgium
State/province [36] 0 0
Halen
Country [37] 0 0
Belgium
State/province [37] 0 0
Ham
Country [38] 0 0
Belgium
State/province [38] 0 0
Linkebeek
Country [39] 0 0
Belgium
State/province [39] 0 0
Ukkel
Country [40] 0 0
Canada
State/province [40] 0 0
British Columbia
Country [41] 0 0
Canada
State/province [41] 0 0
Newfoundland and Labrador
Country [42] 0 0
Canada
State/province [42] 0 0
Ontario
Country [43] 0 0
Canada
State/province [43] 0 0
Quebec
Country [44] 0 0
Czechia
State/province [44] 0 0
Brno
Country [45] 0 0
Czechia
State/province [45] 0 0
Olomouc
Country [46] 0 0
Czechia
State/province [46] 0 0
Praha 2
Country [47] 0 0
Czechia
State/province [47] 0 0
Praha 4
Country [48] 0 0
Czechia
State/province [48] 0 0
Slany
Country [49] 0 0
Czechia
State/province [49] 0 0
Svitavy
Country [50] 0 0
Czechia
State/province [50] 0 0
Usti nad Orlici
Country [51] 0 0
Czechia
State/province [51] 0 0
Znojmo
Country [52] 0 0
Denmark
State/province [52] 0 0
Aalborg
Country [53] 0 0
Denmark
State/province [53] 0 0
Ballerup
Country [54] 0 0
Denmark
State/province [54] 0 0
Vejle
Country [55] 0 0
Finland
State/province [55] 0 0
Helsinki
Country [56] 0 0
Finland
State/province [56] 0 0
OYS
Country [57] 0 0
Germany
State/province [57] 0 0
Berlin
Country [58] 0 0
Germany
State/province [58] 0 0
Köln
Country [59] 0 0
Hong Kong
State/province [59] 0 0
New Territories
Country [60] 0 0
Hungary
State/province [60] 0 0
Budapest
Country [61] 0 0
Hungary
State/province [61] 0 0
Debrecen
Country [62] 0 0
Hungary
State/province [62] 0 0
Dunaujvaros
Country [63] 0 0
Hungary
State/province [63] 0 0
Gyula
Country [64] 0 0
Hungary
State/province [64] 0 0
Kecskemet
Country [65] 0 0
Hungary
State/province [65] 0 0
Komarom
Country [66] 0 0
Hungary
State/province [66] 0 0
Szolnok
Country [67] 0 0
Hungary
State/province [67] 0 0
Zalaegerszeg
Country [68] 0 0
Japan
State/province [68] 0 0
Aichi
Country [69] 0 0
Japan
State/province [69] 0 0
Fukui
Country [70] 0 0
Japan
State/province [70] 0 0
Fukuoka
Country [71] 0 0
Japan
State/province [71] 0 0
Gunma
Country [72] 0 0
Japan
State/province [72] 0 0
Hyogo
Country [73] 0 0
Japan
State/province [73] 0 0
Ibaraki
Country [74] 0 0
Japan
State/province [74] 0 0
Ishikawa
Country [75] 0 0
Japan
State/province [75] 0 0
Kagawa
Country [76] 0 0
Japan
State/province [76] 0 0
Kochi
Country [77] 0 0
Japan
State/province [77] 0 0
Kyoto
Country [78] 0 0
Japan
State/province [78] 0 0
Nagano
Country [79] 0 0
Japan
State/province [79] 0 0
Osaka
Country [80] 0 0
Japan
State/province [80] 0 0
Saitama
Country [81] 0 0
Japan
State/province [81] 0 0
Tokyo
Country [82] 0 0
Netherlands
State/province [82] 0 0
Amsterdam
Country [83] 0 0
Netherlands
State/province [83] 0 0
Hoorn
Country [84] 0 0
Netherlands
State/province [84] 0 0
Utrecht
Country [85] 0 0
Norway
State/province [85] 0 0
Oslo
Country [86] 0 0
Singapore
State/province [86] 0 0
Singapore
Country [87] 0 0
South Africa
State/province [87] 0 0
Gauteng
Country [88] 0 0
South Africa
State/province [88] 0 0
Western Cape
Country [89] 0 0
Spain
State/province [89] 0 0
Andalucía
Country [90] 0 0
Spain
State/province [90] 0 0
Aragón
Country [91] 0 0
Spain
State/province [91] 0 0
Cataluña
Country [92] 0 0
Spain
State/province [92] 0 0
Madrid
Country [93] 0 0
Sweden
State/province [93] 0 0
Göteborg
Country [94] 0 0
Sweden
State/province [94] 0 0
Lund
Country [95] 0 0
Sweden
State/province [95] 0 0
Stockholm
Country [96] 0 0
United Kingdom
State/province [96] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01439880